JP7371029B2 - ベンゼンスルホンアミド化合物および治療剤としてのその使用 - Google Patents

ベンゼンスルホンアミド化合物および治療剤としてのその使用 Download PDF

Info

Publication number
JP7371029B2
JP7371029B2 JP2020568796A JP2020568796A JP7371029B2 JP 7371029 B2 JP7371029 B2 JP 7371029B2 JP 2020568796 A JP2020568796 A JP 2020568796A JP 2020568796 A JP2020568796 A JP 2020568796A JP 7371029 B2 JP7371029 B2 JP 7371029B2
Authority
JP
Japan
Prior art keywords
methyl
amino
azabicyclo
heptan
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020568796A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019241533A5 (https=
JP2021528387A5 (https=
JP2021528387A (ja
Inventor
ティーロ フォッケン，
クリステン ニコル バーフォード，
ヴァーナー アレクサンダー ロフストランド，
マイケル スコット ウィルソン，
アラ ユレブナ ゼノバ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xenon Pharmaceuticals Inc
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of JP2021528387A publication Critical patent/JP2021528387A/ja
Publication of JPWO2019241533A5 publication Critical patent/JPWO2019241533A5/ja
Publication of JP2021528387A5 publication Critical patent/JP2021528387A5/ja
Priority to JP2023129150A priority Critical patent/JP2023138672A/ja
Application granted granted Critical
Publication of JP7371029B2 publication Critical patent/JP7371029B2/ja
Priority to JP2025090964A priority patent/JP2025128218A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2020568796A 2018-06-13 2019-06-13 ベンゼンスルホンアミド化合物および治療剤としてのその使用 Active JP7371029B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023129150A JP2023138672A (ja) 2018-06-13 2023-08-08 ベンゼンスルホンアミド化合物および治療剤としてのその使用
JP2025090964A JP2025128218A (ja) 2018-06-13 2025-05-30 ベンゼンスルホンアミド化合物および治療剤としてのその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862684436P 2018-06-13 2018-06-13
US62/684,436 2018-06-13
PCT/US2019/037011 WO2019241533A1 (en) 2018-06-13 2019-06-13 Benzenesulfonamide compounds and their use as therapeutic agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023129150A Division JP2023138672A (ja) 2018-06-13 2023-08-08 ベンゼンスルホンアミド化合物および治療剤としてのその使用

Publications (4)

Publication Number Publication Date
JP2021528387A JP2021528387A (ja) 2021-10-21
JPWO2019241533A5 JPWO2019241533A5 (https=) 2022-06-15
JP2021528387A5 JP2021528387A5 (https=) 2022-06-15
JP7371029B2 true JP7371029B2 (ja) 2023-10-30

Family

ID=67138087

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020568796A Active JP7371029B2 (ja) 2018-06-13 2019-06-13 ベンゼンスルホンアミド化合物および治療剤としてのその使用
JP2023129150A Withdrawn JP2023138672A (ja) 2018-06-13 2023-08-08 ベンゼンスルホンアミド化合物および治療剤としてのその使用
JP2025090964A Pending JP2025128218A (ja) 2018-06-13 2025-05-30 ベンゼンスルホンアミド化合物および治療剤としてのその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023129150A Withdrawn JP2023138672A (ja) 2018-06-13 2023-08-08 ベンゼンスルホンアミド化合物および治療剤としてのその使用
JP2025090964A Pending JP2025128218A (ja) 2018-06-13 2025-05-30 ベンゼンスルホンアミド化合物および治療剤としてのその使用

Country Status (23)

Country Link
US (2) US10745392B2 (https=)
EP (1) EP3807281A1 (https=)
JP (3) JP7371029B2 (https=)
KR (1) KR102833674B1 (https=)
CN (1) CN112262142B (https=)
AU (1) AU2019285184B2 (https=)
BR (1) BR112020024729A2 (https=)
CA (1) CA3103600A1 (https=)
CL (1) CL2020003197A1 (https=)
CR (1) CR20200613A (https=)
EA (1) EA202092719A1 (https=)
EC (1) ECSP20079861A (https=)
IL (1) IL278949B2 (https=)
JO (1) JOP20200304A1 (https=)
MA (1) MA52888A (https=)
MX (1) MX2020013317A (https=)
NI (1) NI202000098A (https=)
PE (1) PE20211389A1 (https=)
PH (1) PH12020552111A1 (https=)
SA (1) SA520420768B1 (https=)
SG (1) SG11202011862PA (https=)
UA (1) UA127024C2 (https=)
WO (1) WO2019241533A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023138672A (ja) * 2018-06-13 2023-10-02 ゼノン・ファーマシューティカルズ・インコーポレイテッド ベンゼンスルホンアミド化合物および治療剤としてのその使用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3458449T3 (pl) * 2016-05-20 2025-06-23 Xenon Pharmaceuticals Inc. Związki benzenosulfonamidowe i ich zastosowanie jako środki terapeutyczne
CN110325531B (zh) 2016-12-09 2022-05-27 泽农医药公司 苯磺酰胺及其作为治疗剂的用途
KR20210054510A (ko) 2018-08-31 2021-05-13 제논 파마슈티칼스 인크. 헤테로아릴-치환된 술폰아미드 화합물 및 치료제로서의 그의 용도
EP4655291A2 (en) * 2023-01-26 2025-12-03 Merck Sharp & Dohme LLC N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels background
CN117510431A (zh) * 2023-11-08 2024-02-06 浙江雅辰药物科技股份有限公司 一种异噻唑-3-酮及其衍生物、合成方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537282A (ja) 1999-02-20 2002-11-05 ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト 新規置換３−フェノキシ−及び３−フェニルアルキルオキシ−２−フェニル−プロピルアミン
JP2005162726A (ja) 2003-01-24 2005-06-23 Tanabe Seiyaku Co Ltd ピラゾロピリミジン化合物およびその製法
WO2009099177A1 (ja) 2008-02-06 2009-08-13 Taisho Pharmaceutical Co., Ltd. アミノイミダゾール誘導体
WO2017201468A1 (en) 2016-05-20 2017-11-23 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
WO2018093694A1 (en) 2016-11-17 2018-05-24 Merck Sharp & Dohme Corp. Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
JP7022751B2 (ja) 2016-12-09 2022-02-18 ゼノン・ファーマシューティカルズ・インコーポレイテッド ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5877193A (en) 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
EP0981327B1 (en) 1997-05-07 2002-11-06 Galen (Chemicals) Limited Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
CA2349832A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
JP2003504401A (ja) 1999-07-16 2003-02-04 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤を用いる慢性疼痛の治療方法
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
FR2836917B1 (fr) 2002-03-11 2006-02-24 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif
BR0312023A (pt) 2002-06-27 2005-03-22 Novo Nordisk As Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica
WO2004092123A2 (en) 2003-04-10 2004-10-28 Microbia, Inc. Inhibitors of fungal invasion
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
JP2009513523A (ja) 2003-07-08 2009-04-02 ノバルティス アクチエンゲゼルシャフト ベンゼンスルホニルアミノ化合物およびそれらを含む医薬組成物
US8202861B2 (en) 2003-08-08 2012-06-19 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
HU227684B1 (en) 2003-08-29 2011-11-28 Sanofi Aventis Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
JP2008524244A (ja) 2004-12-17 2008-07-10 タケダ サン ディエゴ インコーポレイテッド 水酸化ステロイド脱水素酵素阻害剤
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
CA2624726A1 (en) 2005-10-06 2007-04-12 Sanofi-Aventis 4-oxy-n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
NZ593074A (en) 2005-12-21 2012-04-27 Vertex Pharma sulfonamide-pyrrolidone derivatives as Modulators of Ion Channels
EP2054385A2 (en) 2006-08-15 2009-05-06 F. Hoffmann-Roche AG Phenyl, pyridine and quinoline derivatives
US7968556B2 (en) 2006-10-19 2011-06-28 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and methods of treatment therewith
US8853250B2 (en) 2007-07-13 2014-10-07 Icagen, Inc. Sodium channel inhibitors
CA2693588C (en) 2007-07-13 2015-11-17 Icagen, Inc. Sodium channel inhibitors
WO2009013171A2 (en) 2007-07-24 2009-01-29 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
NZ588983A (en) 2008-06-25 2011-11-25 Daiichi Sankyo Co Ltd Carboxylic acid compound
RU2011103451A (ru) 2008-07-01 2012-08-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Гетероциклические производные в качестве модуляторов ионных каналов
WO2010029300A1 (en) 2008-09-12 2010-03-18 Biolipox Ab Bis aromatic compounds for use in the treatment of inflammation
HUE025013T2 (hu) 2009-01-12 2016-04-28 Pfizer Ltd Szulfonamid-származékok
WO2012004743A1 (en) 2010-07-09 2012-01-12 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
EP2606051B1 (en) 2010-08-20 2016-10-05 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
MX2014001851A (es) 2011-08-17 2014-10-24 Amgen Inc Inhibidores del canal de heteroarilo sodio.
JP2014532660A (ja) 2011-10-28 2014-12-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 電位作動型ナトリウムチャネルにおける選択活性を有するベンゾオキサゾリノン化合物
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
RU2014121984A (ru) 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Бензолсульфонамидные соединения и их применение в качестве терапевтических средств
US8889741B2 (en) 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
US9346798B2 (en) 2012-02-13 2016-05-24 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
CN104718188B (zh) 2012-05-22 2018-08-21 基因泰克公司 N-取代的苯甲酰胺类及其在治疗疼痛中的用途
KR102038607B1 (ko) 2012-10-15 2019-10-30 주식회사 대웅제약 소디움 채널 차단제, 이의 제조방법 및 이의 용도
EP2911668A4 (en) 2012-10-26 2016-07-20 Merck Sharp & Dohme BENZOXAZOLINONE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-CONTROLLED SODIUM CHANNELS
JP2015535252A (ja) 2012-10-26 2015-12-10 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 電位作動型ナトリウムチャネルにおいて選択的活性を有するｎ−置換インダゾールスルホンアミド化合物
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
WO2014201173A1 (en) 2013-06-12 2014-12-18 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
GB201310542D0 (en) 2013-06-13 2013-07-31 Antabio Sas Compounds
JP6407285B2 (ja) 2013-09-09 2018-10-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＲＯＲγ調節因子
UA120353C2 (uk) 2013-09-10 2019-11-25 Хромоселл Корпорейшн Модулятори натрієвого каналу для лікування болю і діабету
WO2015078374A1 (en) 2013-11-27 2015-06-04 Genentech, Inc. Substituted benzamides and methods of use thereof
WO2015077905A1 (en) 2013-11-29 2015-06-04 Merck Sharp & Dohme Corp. Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels
AU2014370407B2 (en) 2013-12-23 2018-03-29 Purdue Pharma L.P. Indazoles and use thereof
WO2016177340A1 (zh) 2015-05-05 2016-11-10 上海海雁医药科技有限公司 双环取代的苯磺酰胺衍生物、其制法与医药上的用途
US10519147B2 (en) 2015-12-18 2019-12-31 Merck Sharp & Dohme Corp. Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
EP3484464B1 (en) 2016-03-22 2020-10-28 Merck Sharp & Dohme Corp. N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels
US10836758B2 (en) 2016-10-27 2020-11-17 Bristol-Myers Squibb Company Acyl sulfonamide NaV1.7 inhibitors
US10745392B2 (en) 2018-06-13 2020-08-18 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
MA53488A (fr) 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques
KR20210054510A (ko) 2018-08-31 2021-05-13 제논 파마슈티칼스 인크. 헤테로아릴-치환된 술폰아미드 화합물 및 치료제로서의 그의 용도

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537282A (ja) 1999-02-20 2002-11-05 ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト 新規置換３−フェノキシ−及び３−フェニルアルキルオキシ−２−フェニル−プロピルアミン
JP2005162726A (ja) 2003-01-24 2005-06-23 Tanabe Seiyaku Co Ltd ピラゾロピリミジン化合物およびその製法
WO2009099177A1 (ja) 2008-02-06 2009-08-13 Taisho Pharmaceutical Co., Ltd. アミノイミダゾール誘導体
WO2017201468A1 (en) 2016-05-20 2017-11-23 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
WO2018093694A1 (en) 2016-11-17 2018-05-24 Merck Sharp & Dohme Corp. Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
JP7022751B2 (ja) 2016-12-09 2022-02-18 ゼノン・ファーマシューティカルズ・インコーポレイテッド ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023138672A (ja) * 2018-06-13 2023-10-02 ゼノン・ファーマシューティカルズ・インコーポレイテッド ベンゼンスルホンアミド化合物および治療剤としてのその使用

Also Published As

Publication number Publication date
BR112020024729A2 (pt) 2021-03-23
AU2019285184A1 (en) 2021-01-28
JOP20200304A1 (ar) 2020-11-25
JP2023138672A (ja) 2023-10-02
AU2019285184B2 (en) 2023-11-16
PH12020552111A1 (en) 2021-08-02
KR20210019507A (ko) 2021-02-22
UA127024C2 (uk) 2023-03-15
IL278949A (en) 2021-01-31
KR102833674B1 (ko) 2025-07-14
PE20211389A1 (es) 2021-07-27
US11325902B2 (en) 2022-05-10
NI202000098A (es) 2021-05-28
IL278949B1 (en) 2024-04-01
ECSP20079861A (es) 2021-03-31
MA52888A (fr) 2021-04-21
US20200361927A1 (en) 2020-11-19
CR20200613A (es) 2021-06-10
CN112262142B (zh) 2023-11-14
JP2025128218A (ja) 2025-09-02
JP2021528387A (ja) 2021-10-21
CN112262142A (zh) 2021-01-22
CL2020003197A1 (es) 2021-04-30
CA3103600A1 (en) 2019-12-19
EP3807281A1 (en) 2021-04-21
IL278949B2 (en) 2024-08-01
US10745392B2 (en) 2020-08-18
SA520420768B1 (ar) 2022-08-30
SG11202011862PA (en) 2020-12-30
MX2020013317A (es) 2021-04-13
US20190382398A1 (en) 2019-12-19
EA202092719A1 (ru) 2021-03-16
WO2019241533A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
JP7371029B2 (ja) ベンゼンスルホンアミド化合物および治療剤としてのその使用
US11299490B2 (en) Benzenesulfonamide compounds and their use as therapeutic agents
US11174268B2 (en) Benzenesulfonamide compouds and their use as therapeutic agents
JP7450606B2 (ja) ヘテロアリール置換スルホンアミド化合物および治療剤としてのそれらの使用
HK40045271A (en) Benzenesulfonamide compounds and their use as therapeutic agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220607

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220607

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230808

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230919

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231018

R150 Certificate of patent or registration of utility model

Ref document number: 7371029

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150